Polyclonal Antibodies Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Polyclonal Antibodies Market Report is Segmented by Product Type (Primary Antibody and Secondary Antibody), Source Type (Rabbit, Mouse, Goat, Horse, and Other Animals), Application (Diagnostic and Clinical Research), End-User (Hospitals, Academic, Biopharmaceutical Industries, Biotechnology Industries, and Diagnostic Centers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Value (in USD) for the Above Segments.

Polyclonal Antibodies Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Polyclonal Antibodies Market Size

Polyclonal Antibodies Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 1.53 Billion
Market Size (2030) USD 2.00 Billion
CAGR (2025 - 2030) 5.53 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Medium

Major Players

Polyclonal Antibodies Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Polyclonal Antibodies Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Polyclonal Antibodies Market Analysis

The Polyclonal Antibodies Market size is estimated at USD 1.53 billion in 2025, and is expected to reach USD 2.00 billion by 2030, at a CAGR of 5.53% during the forecast period (2025-2030).

COVID-19 significantly impacted the polyclonal antibodies market because it possessed a mutation that prevented antibody therapeutics from maintaining antiviral bindings and neutralizing efficacy. For instance, in March 2020, GigaGen, a US-based biotechnology company, developed a treatment called rCIG (recombinant anti-coronavirus 19 hyperimmune gammaglobulin). These polyclonal antibodies could be utilized to develop antibody therapeutics against future COVID-19 threats. According to the journal published by the National Library of Medicine in September 2023, during COVID-19, hundreds of antibodies were developed at preclinical and clinical stages in the format of polyclonal antibodies. Also, because of their potential to bind multiple targets and maintain their neutralizing activity despite mutations, these polyclonal antibodies have shown from animal origin to represent a promising approach. For instance, researchers developed XAV-19, a polyclonal antibody targeting COVID-19 that accelerated the recovery of mild to moderate COVID-19 patients. Thus, COVID-19 had a positive impact on the polyclonal antibodies market, and it was projected to witness lucrative growth in coming years owing to the development of new products and its pivotal role in treating noncurable diseases.

Further, infectious and chronic diseases can be considered as one of the biggest threats to humanity. There are many infectious diseases like Monkey Pox, Ebola, and Zika Virus and others. Antibodies and peptides are key to diagnosing and treating infectious diseases. According to a February 2022, Frontiers article, states that nontyphoidal Salmonella is a common cause of human bacterial enteritis. It causes approximately 93.8 million cases of gastroenteritis worldwide each year. Passive immunization with polyclonal hyperimmune globulin therapy is a proven strategy for delivering immunity. For instance, in May 2023, SAB Biotherapeutics, a biopharmaceutical company, announced the first publication of data for SAB-183 against Pneumonic Plague. It represented that the polyclonal antibodies derived from the transchromosomic bovine vaccinated with the recombinant vaccine increase bacterial opsonization in vitro and protect mice from the plague.

Moreover, chronic diseases like Cancer, Heart Disease, Stroke, Diabetes, Obesity, and many more are increasing globally. According to the article published by the World Health Organization in September 2023, 41 million people die from chronic diseases each year, which is equivalent to 74% of annual deaths. For instance, in the year May 2023, XENOTHERA, a clinical-stage biotechnology company, presented an abstract on its new product, XON7, which targets solid tumor cancer. It has shown promising effects on patients with the new line of treatments for several cancers.

Additionally, polyclonal antibodies are used in various diagnostic kits. It captures and detects antigens in patient samples in enzyme-linked immunosorbent assays. According to the article published by the National Library of Medicine in June 2022, these polyclonal antibodies are more accessible for developing and applying for fast and routine diagnostics in phytopathology and agricultural practice by Western immunoblotting assays. These polyclonal antibodies allow the binding of numerous antigenic determinants of the target, which results in better sensitivity in assays and leads to excellent stability. The biopharmaceutical industries have set up high standards for product efficacy, safety, and quality. For instance in April 2023, SAB Biotherapeutic recently announced positive results from phase 3 clinical trials of SAB-185 in patients with COVID-19 at high risk for severe complications.

However, limited availability of high-quality polyclonal antibodies as multiple cell clones generate polyclonal antibodies, and the resulting antibodies can vary in their affinity and specificity for the antigen. This factor can cause a hurdle in the growth of the polyclonal antibodies market.

Polyclonal Antibodies Industry Overview

The polyclonal antibodies market is consolidated due to a few companies operating globally and regionally. The competitive landscape includes analyzing a few international and local companies, including F. Hoffmann-La Roche AG, Emergent BioSolutions Inc, Creative Diagnostics, Bio-Rad Laboratories, and SAB Biotherapeutics. The key players are involved in various strategic alliances such as acquisitions, collaborations, and new product launches to withstand their position in the global market.

Polyclonal Antibodies Market Leaders

  1. Creative Diagnostics.

  2. F. Hoffmann-La Roche AG

  3. Emergent BioSolutions Inc.

  4. SAB Biotherapeutics

  5. Bio- Rad Laboratories

  6. *Disclaimer: Major Players sorted in no particular order
Polyclonal Antibodies Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Polyclonal Antibodies Market News

  • October 2023: Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens, and assay kits, has recently announced a series of new Anti-Small Molecule Label Antibodies to facilitate the development of nucleic acid lateral flow immunoassay. These antibodies can specifically bind to small molecule labels and offer customers multiple choices with Anti-FAM polyclonal antibodies.
  • February 2023: Roche announced the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody to identify mutation status in patients diagnosed with brain cancer.

Polyclonal Antibodies Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Global Prevalence of Infectious and Chronic Diseases like Cancer.
    • 4.2.2 Use of Polyclonal Antibodies in various Diagnostic Testing and Biopharmaceutical Industries.
  • 4.3 Market Restraints
    • 4.3.1 Limited Availability of High Quality Polyclonal Antibodies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Product Type
    • 5.1.1 Primary Antibody
    • 5.1.2 Secondary Antibody
  • 5.2 By Source
    • 5.2.1 Rabbit
    • 5.2.2 Mouse
    • 5.2.3 Goat
    • 5.2.4 Horse
    • 5.2.5 Other Animals
  • 5.3 By Application
    • 5.3.1 Diagnostic
    • 5.3.2 Clinical Research
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Academic and Research Centers
    • 5.4.3 Bio-Pharmacuetical Industries
    • 5.4.4 Biotechnology Companies
    • 5.4.5 Diagnostics Centers
  • 5.5 Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Creative Diagnostics.
    • 6.1.2 Merck Millipore
    • 6.1.3 Bio- Rad Laboratories
    • 6.1.4 Agilent Technologies
    • 6.1.5 GeneTex
    • 6.1.6 F. Hoffmann-La Roche AG
    • 6.1.7 Lonza Group
    • 6.1.8 Gallus Immunotech
    • 6.1.9 IGY Life Sciences
    • 6.1.10 Emergent BioSolutions Inc.
    • 6.1.11 PerkinElmer Inc.
    • 6.1.12 SAB Biotherapeutics
    • 6.1.13 Immunoprecise Antibodies Ltd.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Polyclonal Antibodies Industry Segmentation

As per the scope of the report, the polyclonal antibody market comprises a group of antibodies that represent the body's normal immunological response to an antigen. These are a collection of immunoglobulin molecules that react to a certain antigen and isolate different epitopes from that antigen. The polyclonal antibody market is segmented by product type (primary antibody and secondary antibody), source type( rabbit, mouse, goat, horse, and other animals), application (diagnostic and clinical research), end-user (hospitals, academics, biopharmaceutical industries, biotechnology industries, and diagnostic centers), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally.

The report offers the value (in USD) for the above segments.

By Product Type Primary Antibody
Secondary Antibody
By Source Rabbit
Mouse
Goat
Horse
Other Animals
By Application Diagnostic
Clinical Research
By End User Hospitals
Academic and Research Centers
Bio-Pharmacuetical Industries
Biotechnology Companies
Diagnostics Centers
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Polyclonal Antibodies Market Research FAQs

How big is the Polyclonal Antibodies Market?

The Polyclonal Antibodies Market size is expected to reach USD 1.53 billion in 2025 and grow at a CAGR of 5.53% to reach USD 2.00 billion by 2030.

What is the current Polyclonal Antibodies Market size?

In 2025, the Polyclonal Antibodies Market size is expected to reach USD 1.53 billion.

Who are the key players in Polyclonal Antibodies Market?

Creative Diagnostics., F. Hoffmann-La Roche AG, Emergent BioSolutions Inc., SAB Biotherapeutics and Bio- Rad Laboratories are the major companies operating in the Polyclonal Antibodies Market.

Which is the fastest growing region in Polyclonal Antibodies Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Polyclonal Antibodies Market?

In 2025, the North America accounts for the largest market share in Polyclonal Antibodies Market.

What years does this Polyclonal Antibodies Market cover, and what was the market size in 2024?

In 2024, the Polyclonal Antibodies Market size was estimated at USD 1.45 billion. The report covers the Polyclonal Antibodies Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Polyclonal Antibodies Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Polyclonal Antibodies Industry Report

Statistics for the 2025 Polyclonal Antibodies market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Polyclonal Antibodies analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Polyclonal Antibodies Market Report Snapshots